Ranjitkar Manandhar N, Kayastha GK, Acharya PK. Dasatinib tyrosine kinase inhibitor as second and third line therapy in chronic myeloid leukemia: outcome of a Nepalese study. JPAHS [Internet]. 2018 Jul. 25 [cited 2024 Oct. 25];5(1):47-56. Available from: https://jpahs.edu.np/index.php/jpahs/article/view/97